

Research article

Open Access

The influence of tumor size and environment on gene expression in commonly used human tumor lines

Michael A Gieseg*, Michael Z Man, Nicholas A Gorski, Steven J Madore, Eric P Kaldjian and Wilbur R Leopold

Address: Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, Michigan, 48105, USA

Email: Michael A Gieseg* - michael.gieseg@pfizer.com; Michael Z Man - michael.man@pfizer.com; Nicholas A Gorski - ngorski@umich.edu; Steven J Madore - steven.madore@pfizer.com; Eric P Kaldjian - eric.kaldjian@umich.edu; Wilbur R Leopold - dick@moleculairimaging.com

* Corresponding author

Published: 15 July 2004

Received: 05 March 2004

BMC Cancer 2004, 4:35 doi:10.1186/1471-2407-4-35

Accepted: 15 July 2004

This article is available from: <http://www.biomedcentral.com/1471-2407/4/35>

© 2004 Gieseg et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The expression profiles of solid tumor models in rodents have been only minimally studied despite their extensive use to develop anticancer agents. We have applied RNA expression profiling using Affymetrix U95A GeneChips to address fundamental biological questions about human tumor lines.

Methods: To determine whether gene expression changed significantly as a tumor increased in size, we analyzed samples from two human colon carcinoma lines (Colo205 and HCT-116) at three different sizes (200 mg, 500 mg and 1000 mg). To investigate whether gene expression was influenced by the strain of mouse, tumor samples isolated from C.B-17 SCID and Nu/Nu mice were also compared. Finally, the gene expression differences between tissue culture and *in vivo* samples were investigated by comparing profiles from lines grown in both environments.

Results: Multidimensional scaling and analysis of variance demonstrated that the tumor lines were dramatically different from each other and that gene expression remained constant as the tumors increased in size. Statistical analysis revealed that 63 genes were differentially expressed due to the strain of mouse the tumor was grown in but the function of the encoded proteins did not link to any distinct biological pathways. Hierarchical clustering of tissue culture and xenograft samples demonstrated that for each individual tumor line, the *in vivo* and *in vitro* profiles were more similar to each other than any other profile. We identified 36 genes with a pattern of high expression in xenograft samples that encoded proteins involved in extracellular matrix, cell surface receptors and transcription factors. An additional 17 genes were identified with a pattern of high expression in tissue culture samples and encoded proteins involved in cell division, cell cycle and RNA production.

Conclusions: The environment a tumor line is grown in can have a significant effect on gene expression but tumor size has little or no effect for subcutaneously grown solid tumors. Furthermore, an individual tumor line has an RNA expression pattern that clearly defines it from other lines even when grown in different environments. This could be used as a quality control tool for preclinical oncology studies.

Background

Preclinical animal models of human tumors represent a major tool for the selection and development of effective anticancer agents. There is a considerable number of well characterized human cancer cell lines, many of which can be grown as solid tumors (either subcutaneously or orthotopically) in immunodeficient mice. The ease of use and low cost of these models make them desirable for screening *in vivo* activity of anticancer compounds as compared to induced or transgenic rodent tumor models. Rodent models also allow pharmacodynamic and pharmacokinetic parameters to be directly measured and related to antitumor efficacy. Commonly used human cancer cell lines, such as the panel of 60 lines (NCI60) used by the Developmental Therapeutics Program at the National Cancer Institute, have been extensively studied at the molecular level *in vitro* and to a lesser extent *in vivo*. Recent advances in genomic technology allow molecular characterization of these models to an extent never before possible using RNA expression profiling, comparative genomic hybridization, proteomic and metabonomic profiling. Ross *et al.* [1] looked at the *in vitro* gene expression in the NCI60 panel. The gene expression pattern for many lines indicated a relationship with the tumor tissue of origin and also correlated with doubling time and drug metabolism. Virtanen *et al.* [2] have analyzed the expression patterns of 85 lung tumor samples from both clinical samples and established tumor lines. The fresh tumors clustered according to pathological subtype with many of the cell lines also clustering within the same groups. Pedersen *et al.* [3] performed a similar study with human small cell lung cancer cell lines and compared them to resected tissue samples. Dan *et al.* [4] recently performed RNA expression profiling on 39 human cancer cell lines and related the gene expression patterns to chemosensitivity of 55 anticancer agents. Zembutsu *et al.* [5] performed a similar study but profiled 85 human cancer xenografts.

What was apparent in all these studies was that each tumor model was distinctly different and could be distinguished from related models using routine data analysis methods. Furthermore, it appears that it is possible to identify models that are no longer true to their origins. Ross *et al.* [1] identified MDA-MB-435 as a possible melanoma derived line, which is at odds with its supposed origins of a metastatic breast carcinoma [6]. However, such identification also raises the possibility that the sample that Ross *et al.* obtained was not the true "MDA-MB-435." Clearly there is the opportunity to use profiling technology as an advanced quality control method that could not only identify mislabeled tumor lines but possibly genetic drift.

While these reports have tremendous value they do not address some basic questions about human tumor mod-

els that could impact the design of *in vivo* drug development studies. For example, most, if not all, xenografts demonstrate Gompertzian growth kinetics with continuously increasing doubling times as they grow larger [7]. Despite this obvious change in biology, it is unknown whether xenografts alter their expression as they increase in size or whether expression differences exist for the same tumor line grown both as a solid tumor in a mouse or in tissue culture. To investigate these questions we grew human colon tumors (HCT-116 and Colo205) in Nu/Nu mice and harvested tumors at three sizes (200 mg, 500 mg, 1000 mg). Isolated RNA was analyzed on Affymetrix GeneChips. The effect of mouse strain on tumor gene expression was also investigated by comparing tumors at 500 mg grown in Nu/Nu and C.B-17 SCID mouse strains. Lastly we profiled additional tumor models to investigate the changes in gene expression that occur when a tumor line is grown *in vivo* or *in vitro*.

Methods

Xenograft and tissue culture methods

Cell lines were grown in DMEM/F12 supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, California). They were passaged in 75-cm² tissue culture flasks in an atmosphere of 5% CO₂ in air and were subcultured weekly, using 0.05% trypsin EDTA (Invitrogen, Carlsbad, California). RNA from tissue culture samples was harvested at mid-log phase. Human tumor xenografts were grown in either Nu/Nu mice or C.B-17 SCID female mice obtained from Charles River Laboratories (Wilmington, Massachusetts) between four and five weeks of age. Mice were housed five to a cage in animal rooms maintained at between 21–25°C with a 12 h alternating dark/light cycle. All animal studies were conducted under Veterinary Use Protocols approved by the Institutional Animal Care and Use Committee. Tumors were maintained by serial passage of 30 mg tumor fragments between animals, implanted subcutaneously into the right axillary region using a trocar needle aseptically. Tumors were passed when the primary had reached between 500 and 1000 mg and were never passed more than ten times. Tumor growth was followed by caliper measurements of perpendicular measures of the tumor. The weight in mg was estimated by the formula: tumor weight = $a(b^2)/2$, where a and b are the tumor length and width respectively in mm. Tumor tissue was harvested immediately following animal sacrifice by excising the tumor and powdering it in a liquid nitrogen cooled crucible and pestle. Tumor powder was stored at -80°C until RNA isolation.

Affymetrix GeneChip

RNA was extracted using TRIZOL® reagent (Invitrogen, Carlsbad, California) according to the manufacturer's protocol. RNA integrity was monitored using denaturing agarose gel electrophoresis in 1X MOPS. Biotinylated target

RNA was prepared from 15 µg of total RNA using the Affymetrix protocol. Briefly, double-stranded cDNA was prepared from the RNA template using a modified oligo-dT primer containing a 5' T7 RNA polymerase promoter sequence and the Superscript Choice System for cDNA Synthesis (Invitrogen, Carlsbad, California). Following phenol-chloroform extraction and ethanol precipitation, one-half of the cDNA reaction (0.5 – 1.0 µg) was used as the template in an *in vitro* transcription reaction containing T7 RNA polymerase, a mixture of unlabeled ATP, CTP, GTP, and UTP, and biotin-11-CTP and biotin-16-UTP (BioArray High Yield Kit, ENZO, Farmingdale, New York). The resulting biotinylated-cRNA "target" was purified on an affinity resin (RNeasy, Qiagen, Valencia, California) and quantified using the convention that 1 O.D. 260 nm corresponds to 40 µg/mL of RNA. Typical yields ranged from 50 – 100 µg with transcript sizes between 3.0 to 0.25 kilonucleotides as determined by denaturing gel electrophoresis. Fifteen micrograms of biotinylated cRNA was randomly fragmented to an average size of 50 nucleotides by incubating at 94 °C for 35 minutes in 40 mM TRIS-acetate, pH 8.1, 100 mM potassium acetate, and 30 mM magnesium acetate. The fragmented cRNA was hybridized in a solution containing 100 mM MES, 1 M [Na⁺], 20 mM EDTA, 0.01% TWEEN 20, 50 pM of Control Oligonucleotide B2, 0.1 mg/mL of sonicated herring sperm DNA, and 0.5 mg/mL BSA for 16 hours at 45 °C on either the Human U95A or the Mouse U74A Affymetrix GeneChips® (Affymetrix, Santa Clara, California). Each hybridization included a mixture of four bacterial biotinylated-RNA transcripts (BioB, BioC, BioD, and cre) spiked at 1.5, 5, 25, and 100 pM, respectively. The hybridization reactions were processed and scanned according to the standard Affymetrix protocols.

Data analysis

All arrays were global scaled to a target intensity value of 600 using the standard Affymetrix protocol. Calculation of the scaling factor, background, noise and percent present, was performed according to Affymetrix protocols using the Data Mining Tool (Affymetrix Santa Clara, California). All resulting data sets were filtered using the absolute call metric (present or absent) using Microsoft Access (Microsoft Corporation, Redmond, Washington). Genes selected had expression levels classified as present at least once in the samples selected for the particular analysis.

To determine the relationship between tumor samples harvested at different sizes the filtered RNA profiling data was analyzed with classic multidimensional scaling (MDS), implemented in R [8,9]. MDS is an unsupervised learning technique that attempts to preserve the relationship between points from high dimensional space at lower dimensional spaces. The program R is a free integrated suite of software facilities for data manipulation,

calculation and graphical display <http://www.r-project.org>.

Analysis of variance (ANOVA) was used to test the effects of tumor size and tumor line, using the following model: $Expression\ of\ gene_i \sim tumor.size + tumor.line + tumor.line*tumor.size$. To test the effect due to mouse background, we used the following model: $Expression\ of\ gene_i \sim mouse\ background$. RNA profiling data filtered on the absolute call metric was used for this analysis and ANOVA was implemented in R. ANOVA is a statistical linear modeling procedure that partitions the total variance into parts corresponding to various sources in the model [10,11]. It has been used previously in microarray data analysis [12-15].

To rigorously select genes with expression differences between samples, ANOVA p-values were adjusted using multiple comparison procedures. Multiple comparison procedures are tools to adjust p-values that might be inflated as a result of performing multiple hypothesis tests. The Benjamini and Hochberg procedure controls the false discovery rate, which is the expected fraction of false discoveries in all rejected hypothesis [16]. This procedure is less stringent than methods controlling the family wise error rate (e.g. the Bonferroni correction); hence it is more powerful.

Hierarchical clustering was performed in GeneSpring 5.0 (Silicon Genetics, Redwood City, California). The distinction calculation from Spotfire DecisionSite 6.2 (Spotfire Inc. Somerville, Massachusetts) was used to select genes differentially expressed in xenograft samples or tissue culture samples. All data from the tissue culture samples that had an *in vivo* pair (8 samples) were selected into one group and all data from the xenograft samples (8 samples) were selected into a second group. Genes were prefiltered using the absolute call metric by selecting genes that were present at least once in the selected samples. A distinction value score and p-value was calculated for each gene. The score (≥ 1) and p-value (≤ 0.001) was then used to select genes that were differentially expressed between xenograft samples and tissue culture samples. To functionally classify gene lists, web resources such as NCBI (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/>) were searched and the data compiled. Further searching for gene associations in PubMed (NCBI) was also performed.

Results

Variation in tumor xenograft gene expression due to size

We focused on two human colon carcinoma xenografts (HCT-116 and Colo205) to investigate the effects of tumor size and mouse strain on gene expression. Samples were harvested in quadruplicate at three different tumor sizes (200 mg, 500 mg and 1000 mg) for both tumor




Figure 1
Multidimensional scaling plot of Colo205 and HCT-116 samples. Multidimensional scaling plot showing the relatedness of individual samples from Colo205 and HCT-116 to each other in 2D space. The color indicates the size of the tumor sample when harvested: red, 200 mg; blue, 500 mg; black, 1000 mg. The size of text indicates the mouse strain the tumor was grown in: small, Nu/Nu; large, C.B-17 SCID. Samples that are more related to each other are closer together. For Colo205 five samples were analyzed.

models grown in Nu/Nu mice (except for the 500 mg sample of Colo205 where five samples were harvested). These sizes were selected as they represent the range at which sensitivity to anticancer agents are traditionally tested and because most models approximate log-linear growth at these sizes. RNA expression profiling data was obtained from Affymetrix U95A GeneChips containing approximately 12600 genes. Genes present (above background)

once or more across all samples were selected for further analysis (approximately 7600 genes).

Initial analysis of the expression data with multi-dimensional scaling (MDS) showed that samples from the same tumor line clustered together and that there was clear separation between samples from HCT-116 and Colo205 (Figure 1). Compared to the profound effect due to tumor




Figure 2
Expected versus observed number of significantly changed genes. The graph shows the number of genes (y-axis) that fall into specific categories (x-axis) based on the ANOVA calculated p-values. The categories are as follows: *Predicted*, number of genes expected by chance alone; *Tumor line effect*, number of genes that fall within the specified ranges due to differences in the tumor line; *Tumor size effect*, number of genes that fall within the specified ranges due to changes in the tumor size; *Mouse strain effect*, number of genes that fall within the specified range due to changes in the mouse strain the tumors were grown in.

line, there was no clear separation among samples of different sizes in the MDS plot, suggesting that there was little alteration in gene expression due to differences in tumor size (tumor size effect).

The result from MDS was further confirmed by analysis of variance (ANOVA). Using ANOVA we modeled the effects of tumor line and tumor size on gene expression. Since in the ANOVA we conducted approximately 7000 statistical tests (on the selected genes), with a p-value cutoff of 0.01, we would expect approximately 70 genes (1% of 7000) scored as significantly changed due to chance alone. Indeed, the observed number of significantly changed genes ($p \leq 0.01$) due to tumor size effect was 154, approximately twice what was predicted by chance alone (Figure 2). In contrast, the number of significantly changed genes due to tumor line effect (4731 genes p -value < 0.01) was far greater than chance alone, indicating the two tumor lines were extremely different as suggested by MDS. The distribution of p-values confirmed the profound effect of tumor line on gene expression with genes affected at all expression levels (Figure 3).

To rigorously identify genes that may suggest functionally significant changes as a tumor increases in size from 200 mg to 1000 mg the ANOVA p-values were adjusted using multiple comparison procedures. Following this analysis none of the previously identified 154 genes had p-values < 0.05 . This indicated that there was no change in gene expression as a human tumor xenograft increased in size from 200 mg to 1000 mg. This was true for both the HCT-116 and the Colo205 tumor lines.

Variation in tumor xenograft gene expression due to mouse strain

Additional RNA samples were prepared from 500 mg HCT-116 tumors grown in C.B-17 SCID mice and hybridized to Affymetrix U95A GeneChips. The expression data were compared to data from the same line grown in Nu/Nu mice harvested at 500 mg. The MDS analysis showed there was no distinct separation or grouping for samples from the two different mouse strains (Figure 1). This suggests that mouse strain played only a small role in altering the expression profiles of HCT-116 tumor samples. However, ANOVA did reveal that considerably more genes




Figure 3

P-value distribution/volcano plot of line and size effect. Scatter plot with mean expression level (log 10) on the x-axis and $-p$ -value (log 10) on y-axis. Each gene is plotted twice, once for the p -value resulting from the tumor-line effect ANOVA (black) and once for the p -value resulting from the tumor-size effect ANOVA (red). The blue line represents a p -value of 0.01. Genes with a lower p -value (more significant) have a higher $-p$ -value log10. There are far more genes with significant p -values due to differences in the tumor lines than due to changes in tumor size.

were altered in their expression due to the mouse background (493 genes) compared to chance alone ($p < 0.01$). To identify genes that may suggest biologically significant differences due to the mouse background effect, the ANOVA p -values were adjusted using multiple comparison procedures. Using the Benjamini and Hockberg procedure [16] 63 genes were found to have a p -value < 0.05

with 32 genes increased in the C.B17-SCID strain and 31 increased in the Nu/Nu strain (Table 1 and 2). Functional classification of these genes using a gene ontology approach did not identify functions that could be linked to known biological pathways. Therefore a biological understanding of the changes in gene expression due to mouse strain remains elusive.

Table 1: Genes with high expression in HCT-116 tumors grown in C.B-17 SCID mice

Function	Affymetrix Probe Set ID	ANOVA p-value	BH p-value ¹	Log ₂ FC ²	Gene Symbol	LocusLink ID	Sequence Probe Derived From	Gene Title
Translation/RNA binding/RNA splicing								
	34733_at	0.00029	0.046	0.5	SF3A1	10291	X85237	splicing factor 3a, subunit 1, 120 kDa
	34829_at	0.00020	0.046	0.4	DKC1	1736	U59151	dyskeratosis congenita 1, dyskerin
	35174_i_at	0.00020	0.046	0.4	EEF1A2	1917	X70940	eukaryotic translation elongation factor 1 alpha 2
	37462_i_at	0.00013	0.042	0.5	SF3A2	8175	L21990	splicing factor 3a, subunit 2, 66 kDa
	39047_at	0.00007	0.030	0.5	SART3	9733	AB020880	squamous cell carcinoma antigen recognised by T cells 3
	40490_at	0.00041	0.049	0.7	DDX21	9188	U41387	DEAD/H box polypeptide 21
Signal transduction								
	33887_at	0.00029	0.046	0.5	HGS	9146	D84064	hepatocyte growth factor-regulated tyrosine kinase substrate
	38019_at	0.00002	0.028	1.0	CSNK1E	1454	L37043	casein kinase 1, epsilon
	38779_r_at	0.00039	0.048	0.8	HDGF	3068	D16431	hepatoma-derived growth factor
	40864_at	0.00029	0.046	0.4	RAC1	5879	D25274	ras-related C3 botulinum toxin substrate
Small Molecule transport								
	32186_at	0.00023	0.046	0.7	SLC7A5	8140	M80244	solute carrier family 7, member 5
	36557_at	0.00003	0.028	0.9	CACNB1	782	M92303	calcium channel, voltage-dependent, beta 1 subunit
	38029_at	0.00031	0.046	0.4	SLC3A2	6520	J02939	solute carrier family, member 2
Protein Complex Assembly								
	31842_at	0.00044	0.050	0.5	BCS1L	617	AF038195	BCS1-like (yeast)
	32575_at	0.00019	0.046	0.4	NAP1L4	4676	U77456	nucleosome assembly protein 1-like 4
Protein transport and folding								
	36945_at	0.00036	0.047	0.5	C12orf8	10961	X94910	chromosome 12 open reading frame 8
	40756_at	0.00017	0.046	0.4	NPM3	10360	AF081280	nucleophosmin/nucleoplasm, 3
Unknown or other functions								
	31670_s_at	0.00023	0.046	0.3	SRP72	6731	U81554	signal recognition particle 72 kDa
	34279_at	0.00005	0.030	2.0	FLJ20719	55672	AL050141	hypothetical protein FLJ20719
	36192_at	0.00003	0.028	0.7	KIAA0193	9805	D83777	KIAA0193 gene product
	36209_at	0.00003	0.028	0.8	BRD2	6046	S78771	bromodomain containing 2
	36210_g_at	0.00035	0.047	1.0	BRD2	6046	S78771	bromodomain containing 2
	36668_at	0.00035	0.047	0.4	DIA1	1727	M28713	diaphorase (NADH)
	37907_at	0.00006	0.030	0.4	F8A	8263	M34677	coagulation factor VIII-associated
	38885_at	0.00000	0.007	1.0	DNA2L	1763	D42046	DNA2 DNA replication helicase 2-like
	39436_at	0.00010	0.039	1.5	BNIP3L	665	AF079221	BCL2/adenovirus E1B 19 kDa interacting protein 3-like
	39758_f_at	0.00030	0.046	0.4	LAMP1	3916	J04182	lysosomal-associated membrane protein 1
	39832_at	0.00007	0.030	0.5	ARS2	51593	AL096723	arsenate resistance protein ARS2
	40589_at	0.00041	0.049	0.9	SNTB2	6645	U40572	syntrophin, beta 2
	40604_at	0.00012	0.040	1.1	DYRK2	8445	Y13493	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
	41062_at	0.00028	0.046	0.7	NSPC1	84759	AA037278	likely ortholog of mouse nervous system polycomb 1
	982_at	0.00011	0.039	0.4	MCM5	4174	X74795	MCM5 minichromosome maintenance deficient 5, cell division cycle 46

¹p-value resulting from Benjamini and Hochberg procedure ²log₂ fold change calculated by dividing expression level from C.B-17 SCID sample by expression level of Nu/Nu sample

Comparison of lines grown in both tissue culture and solid tumor xenografts

To explore the relatedness of different tumor lines to each other and to investigate the gene expression differences between growth in tissue culture and growth as a subcutaneous solid tumor, RNA samples were prepared from the 13 human tumor lines grown in tissue culture to mid-log phase (Table 3). An additional eight RNA samples were obtained of the same lines grown as xenografts in Nu/Nu mice. The gene expression profiling data resulting from hybridizing the 21 samples to Affymetrix U95A GeneChips was filtered for genes classified as present at least once across all samples.

Hierarchical clustering analysis using Spearman rank for samples and Pearson correlation for genes was used to determine the relationship between 13 different human tumor lines (Figure 4). The clustering analysis revealed that for each individual tumor line the xenograft and tissue culture profiles were more similar to each other than any other profile (with one exception). That is, tumor lines clustered together based on their genotypes rather than their growth conditions, suggesting "nature" (genotype) was more influential than "nurture" (growth conditions). This result was confirmed with MDS and principle component analysis (data not shown). The one exception from this pattern was the xenograft sample of ZR-75-1,

which did not cluster on the same node as the ZR-75-1 sample grown in tissue culture. However, subsequently we have found that our xenograft ZR-75-1 line has aberrant biological characteristics that are inconsistent with the known phenotypes of this line.

Although each tissue culture-xenograft sample did cluster together there were many gene changes between the paired samples (Table 4). When fold change values were calculated for each tissue culture xenograft pair and the number of genes with ≥ 2 fold-change tabulated there was a median of 425.5 genes increased in xenografts and 387 decreased. Again the ZR-75-1 sample was aberrant with many more gene changes than the other lines.

Another striking feature revealed by clustering analysis was that none of the tumor lines were particularly similar to each other. The tumor lines did not necessarily cluster based upon the tissue of origin from which each line was thought to be derived. However, a group of breast carcinoma lines that did cluster together (BT474, ZR-75-1, MDA-MB-453, MCF-7, SKBr-3 and MDA-MB-468), although MDA-MB-435 and MDA-MB-231 did not cluster with this group. The two lung carcinoma lines (H2009 and H125) did cluster closely, but MDA-MB-231 and HCT-116 (colon carcinoma) also clustered with this group. MDA-MB-435 and Colo205 clustered independently from all groups.

Selection and functional assessment of differential expressed genes in xenograft or tissue culture samples

Since genes that are co-expressed in a particular environment may provide information about the adaptive changes to the environment, we identified genes that showed a pattern of high expression in xenograft samples or tissue culture samples using Spotfire's DecisionSite calculation. This analysis identified a small number of genes that matched either pattern. There were 36 genes with increased expression in the xenograft samples relative to the tissue cultures samples and 17 genes that showed high expression in the tissue culture samples relative to the xenograft samples (Figure 5). Functional classification of these genes showed that they separated into distinct functional groups (see Table 5 and 6). Many of the genes consistently expressed in tissue culture samples encoded proteins involved in cell division, cell cycle, transcription and translation. In contrast, genes expressed in xenograft samples encoded proteins involved in extracellular matrix, cell adhesion, cell surface receptors transcription and translation.

Discussion

The first part of our study was designed to address whether gene expression patterns in xenografts varied with tumor size. No significant changes (p -value < 0.05) were found

in any genes after statistical analysis of the RNA profiling data. This was a somewhat surprising result as there is evidence to suggest that tumors show size-dependent biological variation in both a clinical setting and as implanted solid tumors in rodents. It is generally assumed clinically that the larger the tumor mass the lower the likelihood of curing the patient, regardless of the treatment [17,18]. Pathological and genetic heterogeneity increase with increasing tumor cell number and contribute to the emergence of clinical drug resistance [19]. As tumors grow larger their vascular surface decreases, intercapillary distance increases, interstitial pressure increases and necrotic foci develop [20]. Tumor doubling times and cell loss also increase with increasing tumor size [17].

Implanted animal tumor models most likely represent clinical end-stage disease and may not necessarily recapitulate clinical behavior seen during tumor development in humans. There are few reports on the molecular and biochemical changes that occur as implanted solid tumors increase in size. Massaad *et al.* [21] found that some drug metabolizing enzyme systems, including glutathione-S-transferases (GST) did change both activity and expression with increasing tumor size in the mouse colon adenocarcinoma Co38.

Preclinical tumor models show variability in response to treatment with a given anti-tumor agent despite being derived from a single tumor and being implanted into inbred mice [22]. This has been attributed to heterogeneity of the host or the tumor cell populations [23,24] along with tumor-to-tumor variations in perfusion and drug distribution [25]. We found there was no significant difference in gene expression between tumors of either the same size or different size as assessed in four replicate animals. If differences in tumor population, host metabolism or perfusion exist between animals implanted with the same tumors, our data suggests they are not detectable using gene expression analysis of the whole tumor.

Our results suggest that once tumor xenografts have grown to 200 mg, physiological influences on tumor transcription (such as the interaction with host stroma, nutrient supply and oxygenation) have reached steady state and do not change appreciably as the tumor grows to 1000 mg. It is also conceivable that tumors smaller and larger than the sizes investigated in this study may show gene expression changes. When a tumor is first implanted the hypoxic environment is likely to drive the expression of pro-angiogenic cytokines that will recruit new vessels to the tumor. As a tumor becomes very large (>2 g) angiogenic factors may again become highly expressed due to the inability for the existing vasculature to adequately support the large tumor mass. We have not excluded the possibility that there may be changes in protein activities




Figure 4
Hierarchical clustering analysis of 13 tumor lines grown in different environments. Hierarchical clustering analysis showing the structure within the data of the 13 tissue culture samples (suffix – TC) and 8 xenograft samples (suffix – X). Samples are displayed vertically, genes are displayed horizontally. A dendrogram of relatedness of the samples is at the top in green. For any two samples, the vertical distance from the sample roots to the first node joining them is a measure of their similarity; the shorter the distance the more similar. The color in each cell of the table represents the median adjusted expression value of each gene. The color scale used to represent the expression ratios is shown on the right, with yellow indicating increased expression relative to the median and blue decreased.

Table 2: Genes with high expression in HCT-116 tumors grown in Nu/Nu mice

Function	Affymetrix Probe Set ID	ANOVA p-value	BH p-value ¹	Log ₂ FC ²	Gene Symbol	LocusLink ID	Sequence Probe Derived From	Gene Title
Translation/RNA binding/RNA splicing								
	32276_at	0.00036	0.047	-0.5	RPL32	6161	X03342	ribosomal protein L32
	32432_f_at	0.00032	0.046	-0.6	RPL15	6138	L25899	ribosomal protein L15
	33614_at	0.00028	0.046	-0.5	RPL18A	6142	X80822	ribosomal protein L18a
	33660_at	0.00039	0.048	-0.5	RPL5	6125	U14966	ribosomal protein L5
	34317_g_at	0.00029	0.046	-0.5	RPS15A	6210	W52024	ribosomal protein S15a
	34345_at	0.00043	0.049	-0.1	C20orf14	24148	AF026031	chromosome 20 open reading frame 14
	398_at	0.00029	0.046	-0.6	DDX18	8886	X98743	DEAD/H box polypeptide 18 (Myc-regulated)
	40887_g_at	0.00017	0.046	-0.5	EEF1A1	1915	L41498	eukaryotic translation elongation factor 1 alpha 1
Signal Transduction								
	35772_at	0.00029	0.046	-0.9	ARHGEF12	23365	AB002380	Rho guanine nucleotide exchange factor (GEF) 12
	36091_at	0.00038	0.048	-0.6	SCAP2	8935	AF051323	src family associated phosphoprotein 2
	40784_at	0.00003	0.028	-0.7	PPP2R5C	5527	Z69030	protein phosphatase 2, regulatory subunit B (B56), gamma isoform
	769_s_at	0.00032	0.046	-0.3	ANXA2	302	D00017	annexin A2
	777_at	0.00010	0.039	-0.6	GDI2	2665	D13988	GDP dissociation inhibitor 2
Unknown or Other Functions								
	1160_at	0.00024	0.046	-0.3	CYC1	1537	J04444	cytochrome c-1
	1226_at	0.00010	0.039	-0.5	ADAM17	6868	U69611	a disintegrin and metalloproteinase domain 17
	31531_g_at	0.00007	0.030	-0.5	ACACB	32	U89344	acetyl-Coenzyme A carboxylase beta
	31684_at	0.00004	0.030	-0.8	ANXA2P1	303	M62896	annexin A2 pseudogene 1
	32518_at	0.00014	0.042	-0.6	ZNF259	8882	AF019767	zinc finger protein 259
	33363_at	0.00041	0.049	-0.1	JTV1	7965	W25934	JTV1 gene
	33389_at	0.00017	0.046	-1.0	CYP51	1595	U23942	cytochrome P450, 51
	33558_at	0.00012	0.039	-0.5	TBX5	6910	Y09445	T-box 5
	33820_g_at	0.00000	0.007	-0.7	HSPA8	3312	X13794	heat shock 70 kDa protein 8
	33937_at	0.00021	0.046	-0.6			AJ011981	Homo sapiens mRNA sequence, IMAGE clone 417820
	34808_at	0.00022	0.046	-0.4			AB023216	KIAA0999 protein
	37218_at	0.00029	0.046	-0.4	BTG3	10950	D64110	BTG family, member 3
	38553_r_at	0.00025	0.046	-1.3	BAP29	55973	AI984786	B-cell receptor-associated protein BAP29
	38589_i_at	0.00042	0.049	-0.6	PTMA	5757	M14630	prothymosin, alpha (gene sequence 28)
	39167_r_at	0.00045	0.050	-1.2	SERPINH2	872	D83174	serine (or cysteine) proteinase inhibitor, clade H, member 2
	418_at	0.00004	0.030	-0.5	MKI67	4288	X65550	antigen identified by monoclonal antibody Ki-67
	893_at	0.00003	0.028	-0.4	E2-EPF	27338	M91670	ubiquitin carrier protein
	932_i_at	0.00031	0.046	-0.8	ZNF91	7644	L11672	zinc finger protein 91

¹p-value resulting from Benjamini and Hochberg procedure ²log₂ fold change calculated by dividing expression level from C.B-17 SCID sample by expression level of Nu/Nu sample

Table 3: Human tumor lines used in this study

Tumor	Tissue of Origin	Xenograft sample	Tissue culture sample
BT-474	Breast	No	Yes
MCF-7	Breast	No	Yes
MDA-MB-231	Breast	Yes	Yes
MDA-MB-435	Breast	Yes	Yes
MDA-MB-453	Breast	No	Yes
MDA-MB-468	Breast	Yes	Yes
SKBr-3	Breast	No	Yes
ZR-75-1	Breast	Yes	Yes
Colo205	Colon	Yes	Yes
HCT-116	Colon	Yes	Yes
H125	Lung	Yes	Yes
H2009	Lung	No	Yes
A431	Squamous cell	Yes	Yes




Figure 5
Heat-map plot of differential expressed genes in xenograft or tissue culture samples. Heat-map plot showing the genes selected as differentially expressed between the tissue culture and xenograft samples. The samples are displayed vertically, genes are displayed horizontally. Yellow indicates high expression while blue indicates low expression, relative to the median expression for each gene across all samples

Table 4: Number of genes with fold change values greater than or equal to 2 with tissue culture sample as the baseline

Tumor line	Number of genes with ≥ 2 fold increase	Number of genes with ≥ 2 fold decrease	Total with ≥ 2 fold change
A431	542	650	1192
Colo205	447	328	775
H125	335	304	639
HCT-116	351	393	744
MDA-MB-231	489	381	870
MDA-MB-435	404	519	923
MDA-MB-468	381	204	585
ZR-75-1	889	1218	2107
Median	425.5	387	822.5

or levels, or that other tumor lines may show changes as the size increases. But since the phenomenon was independently observed in two tumor lines it suggests it may be common to many other lines. The results also imply that tumors harvested within this size range without drug treatment should be very comparable. It remains possible that selective isolation and analysis of tumor regions or subpopulations by microdissection may identify expression differences.

By comparing the same tumor line grown in different mouse strains we identified 63 genes with a significant change in gene expression with biological functions ranging from cellular signaling, RNA processing and translation. Although different genes were differentially expressed in different mouse strains, particular gene functions did not associate with one strain. Therefore, the biological significance of these changes remains unclear. It should be noted that although the changes were statistically significant, in general the magnitude of the change was small. Only 12% of the significant genes displayed a change greater or equal to 2-fold. This raises the question of whether statistical significance equates to biological significance and how relevant thresholds can be determined for analyzing expression profiling data.

In the second part of the study we compared the gene expression patterns of tumor lines grown as xenografts with the same lines grown in tissue culture. We found that each xenograft – tissue culture pair was more similar to one another than any other line. This has been previously observed with RNA expression profiling of small cell lung cancer lines grown as both xenografts and tissue culture [3]. In our data, the one exception to this clustering pattern, ZR-75-1, exhibited aberrant growth characteristics; it had a rapid doubling time (2–3 days)

and was not estrogen dependent as has been reported [26,27].

There was a gene expression pattern consistent with growth either in a xenograft or tissue culture environment, but remarkably it consisted of only a small number of genes. We identified 36 genes with high relative expression in xenograft samples and 17 genes with high relative expression in tissue culture samples. Their biological functions were consistent with the differences between a tissue culture sample and a xenograft sample. Genes expressed at increased levels in tissue culture samples were primarily involved in cell division, cell cycle, transcription and translation and were consistent with a greater percentage of cycling cells in the tissue culture samples, which we have previously observed with flow cytometry (data not shown). Many of the genes expressed in xenograft samples encoded for proteins involved in extracellular matrix, cell adhesion, cell surface receptors transcription and translation and suggest increased interactions with an *in vivo* stromal environment, including the development of a 3-dimensional matrix.

There are several reports in the literature of tumor line expression profiling studies demonstrating that lines derived from a common tissue of origin group together in most cases [1,4,5]. We observed that most of the breast tumor lines clustered together but the other lines generally did not show clustering patterns based upon tissue of origin. However, our study evaluated fewer samples and consisted predominantly of breast cancer tumor lines with only two representatives of non-small cell lung cancer and colon cancer.

Since each tumor line was substantially different to every other line tested it suggests that it would be possible to identify a group of genes that could be used to distinguish

Table 5: Genes with high expression in xenograft samples

Function	Affymetrix Probe Set ID	Gene Symbol	LocusLink ID	Sequence Probe Set Derived From	Gene Title
Extracellular Matrix/Cell Adhesion					
	31574_i_at			M14087	Beta-galactoside-binding lectin, mRNA sequence
	31810_g_at	CNTN1	1272	Z21488	contactin 1
	32305_at	COL1A2	1278	J03464	collagen, type I, alpha 2
	32701_at	ARVCF	421	U51269	armadillo repeat gene deletes in velocardiofacial syndrome
	36298_at	PRPH	5630	L14565	peripherin
	38181_at	MMP11	4320	X57766	matrix metalloproteinase 11 (stromelysin 3)
	38570_at	HLA-DOB	3112	X03066	major histocompatibility complex, class II, DO beta
	38614_s_at	OGT	8473	U77413	O-linked N-acetylglucosamine (GlcNAc) transferase
Cell surface receptor					
	33950_g_at	CRHR2	1395	AF011406	corticotropin releasing hormone receptor 2
	35485_at	GRM4	2914	X80818	glutamate receptor, metabotropic 4
	35503_at	HTR1B	3351	M81590	5-hydroxytryptamine (serotonin) receptor 1B
	36277_at	CD3E	916	M23323	CD3E antigen, epsilon polypeptide (TiT3 complex)
	41190_at	TNFRSF25	8718	U83598	tumor necrosis factor receptor superfamily, member 25
Transcription/transcription factor					
	34786_at	JMJD1	55818	AB018285	zinc finger protein
	36944_f_at	PLAGL1	5325	U72621	pleiomorphic adenoma gene-like 1
	37491_at	TAFI	6872	D90359	TAFI RNA polymerase II, TATA box binding protein-associated factor
	38216_at	TRIP8	9323	L40411	thyroid hormone receptor interactor 8
Intracellular transport					
	32228_at	AP2A2	161	AB020706	adaptor-related protein complex 2, alpha 2 subunit
	33779_at	VAMP1	6843	AF060538	vesicle-associated membrane protein 1 (synaptobrevin 1)
Translation/RNA binding/RNA splicing					
	1556_at	RBM5	10181	U23946	RNA binding motif protein 5
	31896_at	NAG	51594	AL050281	neuroblastoma-amplified protein
Unknown or other functions					
	1155_at			J03069	
	1529_at	I3CDNA73	10129	U50534	hypothetical protein CG003
	31525_s_at			J00153	
	31652_at	KIAA1000	22989	AB023217	KIAA1000 protein
	32355_at	DKFZP564D166	26115	AL050270	putative ankyrin-repeat containing protein
	36811_at			U24389	
	37979_at	YAPI	10413	X80507	Yes-associated protein 1, 65 kDa
	39499_s_at	PARD3	56288	W25794	par-3 partitioning defective 3 homolog
	40928_at	WSB1	26118	W26496	SOCS box-containing WD protein SWIP-1
	41113_at	KIAA0557	26048	A1871396	KIAA0557 protein
	41328_s_at	EML2	24139	AL096717	echinoderm microtubule associated protein like 2
	40856_at	SERPINF1	5176	U29953	serine (or cysteine) proteinase inhibitor, clade F, member 1
	32833_at	CLK1	1195	M59287	CDC-like kinase 1
	39451_i_at	IDS	3423	AF050145	iduronate 2-sulfatase (Hunter syndrome)
	36386_at	PDK1	5163	L42450	pyruvate dehydrogenase kinase, isoenzyme 1

individual lines. Also, it has been our experience that it is possible to identify aberrant samples resulting from labeling error by expression profiling that were missed by other methods. What is less clear is whether genetic drift causes changes in RNA expression that can be identified using RNA profiling technology. Recently a report has been published showing that MCF-7 sublines were substantially different to each other both at the genetic and RNA expression levels [28] suggesting that variation within individual lines can be identified. Given this, it seems reasonable that RNA expression profiling could be used as a comprehensive methodology for identifying aberrant or incorrectly labeled samples. This would

provide an additional quality control tool to standardize tumor models and the *in vivo* testing of therapeutic agents.

Conclusions

Our data suggest that the environment a tumor line is grown in can have a significant effect on gene expression even though tumor size has little or no effect for a subcutaneously grown solid tumor. Furthermore, an individual tumor line has an RNA expression pattern that clearly defines it from other lines even when grown in different environments such as tissue culture or *in vivo*. Routine RNA expression profiling of a selected set of genes could be used as a quality control tool for preclinical oncology

Table 6: Genes with high expression in tissue culture samples

Function	Affymetrix ProbeSet ID	Gene Symbol	LocusLink ID	Sequence ProbeSet Derived From	Gene Title
Cell division	34851_at	STK6	6790	AF011468	serine/threonine kinase 6
	33346_r_at	TUBG1	7283	M61764	tubulin, gamma 1
	35995_at	ZWINT	11130	AF067656	ZW10 interactor
	37171_at	KNLS5	9493	X67155	kinesin-like 5 (mitotic kinesin-like protein 1)
Cell cycle	34736_at	CCNBI	891	M25753	cyclin B1
	37458_at	CDC45L	8318	AJ223728	CDC45 cell division cycle 45-like (S. cerevisiae)
	38804_at	CSE1L	1434	AF053641	CSE1 chromosome segregation 1-like (yeast)
Translation/RNA binding/RNA splicing	35323_at	EIF3S9	8662	U78525	eukaryotic translation initiation factor 3, subunit 9 eta, 116 kDa
	38679_g_at	SNRPE	6635	AA733050	small nuclear ribonucleoprotein polypeptide E
	41460_at	RBM14	10432	AF080561	RNA binding motif protein 14
Transcription/transcription factor	39664_at	CKN1I	1161	U28413	Cockayne syndrome I (classical)
	41332_at	POLR2E	5434	D38251	polymerase (RNA) II (DNA directed) polypeptide E, 25 kDa
Unknown or other functions	35715_at	DKFZP564M082	25906	AL080071	DKFZP564M082 protein
	40758_at	ICT1	3396	X81788	immature colon carcinoma transcript 1
	1749_at	GCDH	2639	AD000092	glutaryl-Coenzyme A dehydrogenase
	40134_at	ATP5J2	9551	AF047436	ATP synthase, subunit f, isoform 2
	41400_at	TK1	7083	K02581	thymidine kinase 1, soluble

studies and would allow the standardization of tumor models used worldwide.

Competing interests

None declared.

Authors' contributions

MAG carried out sample preparation, RNA isolation, data analysis and drafted the manuscript. MZM performed the MDS analysis, ANOVA and statistical analysis. NAG performed the animal procedures, sample preparation and RNA isolation. SJM directed the team who carried out the Affymetrix GeneChip hybridizations and initial data processing. EPK conceived part of the study and participated in its design. WRL conceived part of the study and participated in its design.

Acknowledgements

We kindly acknowledge Dr Sarah Fowler for assistance with proofing this manuscript and Dr William Elliott for helpful discussion about the growth characteristics of solid tumor xenografts.

References

- Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de RM, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: **Systematic variation in gene expression patterns in human cancer cell lines.** *Nat Genet* 2000, **24**:227-235.
- Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, Nomura H, Jones MH: **Integrated classification of lung tumors and cell lines by expression profiling.** *Proc Natl Acad Sci USA* 2002, **99**:12357-12362.

- Pedersen N, Mortensen S, Sorensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS: **Transcriptional gene expression profiling of small cell lung cancer cells.** *Cancer Res* 2003, **63**:1943-1953.
- Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T: **An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines.** *Cancer Res* 2002, **62**:1139-1147.
- Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y: **Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.** *Cancer Res* 2002, **62**:518-527.
- Cailleau R, Olive M, Cruciger QV: **Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.** *In Vitro* 1978, **14**:911-915.
- Jackson RC: **From The Growth Kinetics of Large Tumors.** In *The Theoretical Foundations of Cancer Chemotherapy Introduced by Computer Models* Edited by: Jackson RC. San Diego, California: Academic Press Inc; 1992:259-298.
- Ihaka R, Gentleman RR: **A Language for Data Analysis and Graphics.** *Journal of Computational and Graphical Statistics* 1996, **5**:299-314.
- Venables WN, Ripley BD: *Modern Applied Statistics with S-PLUS* Second edition. Springer; 1997.
- Fisher RD: *Statistical methods for research workers* London: Oliver and Boyd; 1950.
- Fisher LD, van Belle G: *Biostatistics: a methodology for the health sciences* New York: John Wiley & Sons Inc; 1993.
- Kerr MK, Martin M, Churchill GA: **Analysis of variance for gene expression microarray data.** *J Comput Biol* 2000, **7**:819-837.
- Coombes KR, Highsmith WE, Krogmann TA, Baggerly KA, Stivers DN, Abruzzo LV: **Identifying and quantifying sources of variation in microarray data using high-density cDNA membrane arrays.** *J Comput Biol* 2002, **9**:655-669.
- Pritchard CC, Hsu L, Delrow J, Nelson PS: **Project normal: defining normal variance in mouse gene expression.** *Proc Natl Acad Sci USA* 2001, **98**:13266-13271.
- Pavlidis P, Noble WS: **Analysis of strain and regional variation in gene expression in mouse brain.** *Genome Biol* 2001, **2**:1-15.

16. Benjamini Y, Hochberg Y: **Controlling the false discovery rate; a practical and powerful approach to multiple testing.** *Journal of the Royal Statistical Society Series B* 1995, **57**:289-300.
17. DeVita VT Jr: **The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer.** *Cancer* 1983, **51**:1209-1220.
18. Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, Hughes K: **Predicting the survival of patients with breast carcinoma using tumor size.** *Cancer* 2002, **95**:713-723.
19. Baylin SB: **From Clonal selection and heterogeneity of human solid neoplasms.** In *Design of Models for Testing Cancer Therapeutic Agents* Edited by: Fidler IJ, White RJ. New York: Van Nostrand Reinhold; 1981:50-63.
20. Jain RK: **Delivery of novel therapeutic agents in tumors: physiological barriers and strategies.** *J Natl Cancer Inst* 1989, **81**:570-576.
21. Massaad L, Chabot GG, Toussaint C, Koscielny S, Morizet J, Bissery MC, Gouyette A: **Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38.** *Cancer Chemother Pharmacol* 1994, **34**:497-502.
22. Schabel FM, Griswold DP, Corbett TH, Laster WR, Lloyd HH, Rose WC: **From Variable response of advanced solid tumors of mice to treatment with anticancer drugs.** In *Design of Models for Testing Cancer Therapeutic Agents* Edited by: Fidler IJ, White RJ. New York: Van Nostrand Reinhold; 1981:95-113.
23. Nelson JA, Hokanson JA, Jenkins VK: **Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma.** *Cancer Chemother Pharmacol* 1982, **9**:148-155.
24. Trope C: **From Different susceptibilities of tumor cell subpopulations to cytotoxic agents.** In *Design of Models for Testing Cancer Therapeutic Agents* Edited by: Fidler IJ, White RJ. New York: Van Nostrand Reinhold; 1981:64-79.
25. Simpson-Herren L, Noker PE, Wagener SD: **Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity.** *Cancer Chemother Pharmacol* 1988, **22**:131-136.
26. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C: **Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.** *Int J Cancer* 2002, **99**:273-278.
27. Cameron DA, Ritchie AA, Langdon S, Anderson TJ, Miller WR: **Tamoxifen induced apoptosis in ZR-75-1 breast cancer xenografts antedates tumor regression.** *Breast Cancer Res Treat* 1997, **45**:99-107.
28. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, Nguyen C, Birnbaum D, Douzery EJ, Cohen P, Theillet C: **Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications.** *BMC Cancer* 2003, **3**:13.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/4/35/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

